Exhibits
8-K
from 8-K
5 pages
8-K
10/16/24
EX-99.1
from 8-K
5 pages
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients With Moderate to Severe Systemic Lupus Erythematosus
10/16/24
EX-99.2
from 8-K
55 pages
CORPORATE OVERVIEW October 2024
10/16/24
Graphics & Data Files
GRAPHIC
from 8-K
cgem-ex99_2s1.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s2.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s3.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s4.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s5.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s6.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s7.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s8.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s9.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s10.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s11.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s12.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s13.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s14.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s15.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s16.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s17.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s18.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s19.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s20.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s21.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s22.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s23.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s24.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s25.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s26.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s27.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s28.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s29.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s30.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s31.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s32.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s33.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s34.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s35.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s36.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s37.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s38.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s39.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s40.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s41.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s42.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s43.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s44.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s45.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s46.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s47.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s48.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s49.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s50.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s51.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s52.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s53.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s54.jpg
10/16/24
GRAPHIC
from 8-K
cgem-ex99_2s55.jpg
10/16/24
